Analysts Are Bullish on These Healthcare Stocks: ADAP, SELB


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Adaptimmune Therapeutics (NASDAQ: ADAP) and Selecta Biosciences (NASDAQ: SELB) with bullish sentiments.

Adaptimmune Therapeutics (NASDAQ: ADAP)

In a report released today, Eric Schmidt from Cowen & Co. maintained a Buy rating on Adaptimmune Therapeutics (NASDAQ: ADAP). The company’s shares opened today at $13.74, close to its 52-week high of $14.20.

According to TipRanks.com, Schmidt is a top 25 analyst with an average return of 42.8% and a 60.9% success rate. Schmidt covers the Healthcare sector, focusing on stocks such as Merrimack Pharmaceuticals, Alexion Pharmaceuticals, and Akcea Therapeutics Inc.

Currently, the analyst consensus on Adaptimmune Therapeutics is Strong Buy and the average price target is $17.50, representing a 27.4% upside.

In a report released today, Raymond James also maintained a Buy rating on the stock with a $20 price target.

See today’s analyst top recommended stocks >>

Selecta Biosciences (NASDAQ: SELB)

In a report released today, John Newman from Canaccord Genuity maintained a Buy rating on Selecta Biosciences (NASDAQ: SELB), with a price target of $30. The company’s shares opened today at $10.67.

Newman observed:

“We continue to expect positive data for the five-dose combination Phase 2 cohorts in 3Q18, and anticipate sustained serum uric acid suppression without ADAs. Selecta will present data for patients receiving 0.10 – 0.15 mg/kg SVP rapamycin combined with 0.2 mg/kg pegsiticase. The company plans to present multiple cohorts with up to n=20 patients per group. We expect data in 3Q18 to include a number of patients who have completed the full 5/6 dose combination regimen.”

According to TipRanks.com, Newman is a 5-star analyst with an average return of 15.9% and a 44.9% success rate. Newman covers the Healthcare sector, focusing on stocks such as Hutchison China MediTech Ltd, Synergy Pharmaceuticals Inc, and Aileron Therapeutics Inc.

Currently, the analyst consensus on Selecta Biosciences is Moderate Buy and the average price target is $30, representing a 181.2% upside.

In a report released today, Mizuho Securities also maintained a Buy rating on the stock with a $30 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on SELB:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts